摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(2-aminopyrimidin-4-ylamino)-2-methylphenol | 933045-98-8

中文名称
——
中文别名
——
英文名称
5-(2-aminopyrimidin-4-ylamino)-2-methylphenol
英文别名
5-[(2-aminopyrimidin-4-yl)amino]-2-methylphenol
5-(2-aminopyrimidin-4-ylamino)-2-methylphenol化学式
CAS
933045-98-8
化学式
C11H12N4O
mdl
——
分子量
216.242
InChiKey
ALWYMNCEVSZVOO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    84.1
  • 氢给体数:
    3
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted piperidines
    申请人:——
    公开号:US20030186963A1
    公开(公告)日:2003-10-02
    A novel class of substituted piperidines, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
    一种新型的替代哌啶类化合物,包括它们的药物组合物以及在治疗和/或预防与组胺H3受体相关的疾病和紊乱方面的用途。更具体地说,这些化合物对于治疗和/或预防与组胺H3受体相互作用有益的疾病和紊乱是有用的。
  • PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL
    申请人:KANTO DENKA KOGYO CO., LTD.
    公开号:US20190169107A1
    公开(公告)日:2019-06-06
    A simple production process is provided of a perfluoroalkyl compound that uses monohydroperfluoroalkane as a starting material, the perfluoroalkyl compound being an important intermediate of organic electronic materials, medicine, agricultural chemicals, functional polymer materials and the like. With monohydroperfluoroalkane is reacted a base and then a carbonyl compound to produce an alcohol having a perfluoroalkyl group. For example, potassium hydroxide is made to interact with trifluoromethane, and a reaction with a carbonyl compound is induced to produce an alcohol having a trifluoromethyl group.
    提供了一种简单的生产过程,使用单羟基全氟烷作为起始物质来制备全氟烷基化合物,该全氟烷基化合物是有机电子材料、药物、农药、功能性聚合物材料等的重要中间体。使用单羟基全氟烷与碱反应,再与羰基化合物反应,可以产生具有全氟烷基的醇。例如,可以将氢氧化钾三氟甲烷相互作用,并诱导与羰基化合物反应,以产生具有三甲基基团的醇。
  • Compounds and Methods for the Treatment of Viruses and Cancer
    申请人:Jorgensen William L.
    公开号:US20100222352A1
    公开(公告)日:2010-09-02
    The present invention relates to compounds according to the formula I: Where R a is H or an optionally OH-substituted C 1 -C 3 alkyl; R 1 is OR 1 , an optionally substituted C 4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R 1 is an optionally substituted C 1 -C 14 hydrocarbyl group or an optionally substituted heterocyclic group; R 2 , R 3 and R 4 are each independently H, an optionally substituted C 1 -C 4 alkyl group (preferably CH 3 , CH 2 CH 3 or CF 3 ), halogen (preferably F, Cl, Br), OR, CN, NO 2 , a C 1 -C 6 thioether, a C 1 -C 6 thioester group, an optionally substituted CO 2 R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R 4 is H); R is H or an optionally substituted C 1 -C 6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.
    本发明涉及公式I的化合物:其中R为H或可选择的OH取代的C1-C3烷基; R1为OR1,可选择取代的C4-12碳环基,可饱和或不饱和(包括芳香族)或可选择取代的杂环基; R1为可选择取代的C1-C14烃基或可选择取代的杂环基; R2、R3和R4各自独立地为H、可选择取代的C1-C4烷基(优选为CH3、CH2 或CF3)、卤素(优选为F、Cl、Br)、OR、CN、NO2、C1-C6醚、C1-C6酯基、可选择取代的CO2R基团、可选择取代的COR基团或可选择取代的OCOR基团(优选R4为H); R为H或可选择取代的C1-C6烷基; RHET为可选择取代的杂环基;以及其药学上可接受的盐、溶剂或多晶体。
  • SUBSTITUTED PIPERIDINES
    申请人:Dorwald Florencio Zaragoza
    公开号:US20100222386A1
    公开(公告)日:2010-09-02
    A novel class of substituted piperidines, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
    一种新的取代哌啶类化合物、包含它们的药物组合物和在治疗和/或预防与组胺H3受体相关的疾病和紊乱方面的应用。更具体地说,这些化合物可用于治疗和/或预防与组胺H3受体相互作用有益的疾病和紊乱。
  • Compounds and methods for the treatment of viruses and cancer
    申请人:Jorgensen William L.
    公开号:US09018209B2
    公开(公告)日:2015-04-28
    The present invention relates to compounds according to the formula I: Where Ra is H or an optionally OH-substituted C1-C3 alkyl; R1 is OR1, an optionally substituted C4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R1 is an optionally substituted C1-C14 hydrocarbyl group or an optionally substituted heterocyclic group; R2, R3 and R4 are each independently H, an optionally substituted C1-C4 alkyl group (preferably CH3, CH2CH3 or CF3), halogen (preferably F, Cl, Br), OR, CN, NO2, a C1-C6 thioether, a C1-C6 thioester group, an optionally substituted CO2R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R4 is H); R is H or an optionally substituted C1-C6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.
    本发明涉及化合物I式:其中Ra为H或有选择地取代的C1-C3烷基;R1为OR1,有选择地取代的C4-12碳环基,可以是饱和或不饱和的(包括芳香族)或有选择地取代的杂环基;R1为有选择地取代的C1-C14烃基或有选择地取代的杂环基;R2、R3和R4各自独立地为H,有选择地取代的C1-C4烷基(优选为CH3、CH2 或CF3)、卤素(优选为F、Cl、Br)、OR、CN、NO2、C1-C6醚、C1-C6酯基、有选择地取代的CO2R基、有选择地取代的COR基或有选择地取代的OCOR基(优选为R4为H);R为H或有选择地取代的C1-C6烷基;RHET为有选择地取代的杂环基;以及其药学上可接受的盐、溶剂或多晶形式。
查看更多